| Literature DB >> 33181693 |
Joon Woo Kim1, Hyoseon Choi, Jisang Jung, Hyun Jung Kim.
Abstract
Prediction of aspiration pneumonia development in at-risk patients is vital for implementation of appropriate interventions to reduce morbidity and mortality. Unfortunately, studies utilizing a comprehensive approach to risk assessment are still lacking. The objective of this study was to analyze the clinical features and videofluoroscopic swallowing study (VFSS) findings that predict aspiration pneumonia in patients with suspected dysphagia.Medical records of 916 patients who underwent VFSS between September 2014 and June 2018 were retrospectively analyzed. Patients were divided into either a pneumonia group or a non-pneumonia group based on diagnosis of aspiration pneumonia. Clinical information and VFSS findings were evaluated.One hundred seven patients (11.7%) were classified as having pneumonia. Multivariate analysis indicated that aspiration during the 2- cubic centimeter thick-liquid trial of VFSS (odds ratio [OR] = 3.23, 95% confidence interval [CI]: 1.93-5.41), smoking history (OR = 2.63, 95% CI: 1.53-4.53), underweight status (OR = 2.27, 95% CI: 1.31-3.94), abnormal pharyngeal delay time (OR = 1.60, 95% CI: 1.01-2.53), and a Penetration-Aspiration Scale level of 8 (OR = 3.73, 95% CI: 2.11-6.59) were significantly associated with aspiration pneumonia development. Integrated together, these factors were used to develop a predictive model for development of aspiration pneumonia (DAP), with a sensitivity of 82%, specificity of 56%, and an area under the receiver operating characteristic curve of 0.73.The best predictors for DAP included videofluoroscopic findings of aspiration during a 2-cubic centimeter thick-liquid trial, prolonged pharyngeal delay time, a Penetration-Aspiration Scale level of 8, history of smoking, and underweight status. These 5 proposed determinants and the associated DAP score are relatively simple to assess and may constitute a clinical screening tool that can readily identify and improve the management of patients at risk for aspiration pneumonia.Entities:
Mesh:
Year: 2020 PMID: 33181693 PMCID: PMC7668488 DOI: 10.1097/MD.0000000000023177
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
Figure 1Patient recruitment flow chart, including number of subjects. VFSS = videofluoroscopic swallowing study.
Demographics and analyzed data of study subjects.
| Variables | Pneumonia group (n = 107) | Non-pneumonia group (n = 809) | OR | 95% CI | |
| Age (yr)a | 73.44 ± 11.05 | 71.13 ± 13.43 | .089 | ||
| Sex-maleb | 67 (62.6) | 419 (51.8) | .036∗ | 1.559 | 1.209–2.361 |
| Etiology-neurologicb | 85 (79.4) | 694 (85.8) | .086 | 0.640 | 0.385–1.065 |
| Past history or current accompanying conditionb | |||||
| Hypertension | 70 (65.4) | 456 (56.4) | .076 | 1.465 | 0.960–2.233 |
| Heart failure | 4 (3.7) | 30 (3.7) | .988 | 1.008 | 0.348–2.920 |
| Diabetes mellitus | 46 (43.0) | 277 (34.2) | .076 | 1.448 | 0.962–2.181 |
| Tuberculosis | 4 (3.7) | 29 (3.6) | .936 | 1.045 | 0.360–3.031 |
| COPD | 8 (7.5) | 49 (6.1) | .569 | 1.253 | 0.577–2.724 |
| Hyperlipidemia | 9 (8.4) | 88 (10.9) | .437 | 0.752 | 0.367–1.542 |
| Hepatitis | 3 (2.8) | 10 (1.2) | .210 | 2.305 | 0.624–8.510 |
| Smoking | 29 (27.1) | 117 (14.5) | .001∗ | 2.199 | 1.376–3.515 |
| Alcohol | 66 (61.7) | 508 (62.8) | .823 | 0.954 | 0.630–1.444 |
| BMI (kg/m2)c | .013∗ | 1.390 | 1.071–1.804 | ||
| 18.5–25.0 | 64 (59.8) | 550 (68.0) | .092 | 0.701 | 0.463–1.060 |
| ≥ 25.0 | 20 (18.7) | 166 (20.5) | .898 | 1.035 | 0.609–1.761 |
| < 18.5 | 23 (21.5) | 93 (11.5) | .005∗∗ | 2.125 | 1.258–3.592 |
| Functional level-ambulationb | 10 (9.3) | 109 (13.5) | .236 | 1.510 | 0.764–2.986 |
| Number of neurologic comorbiditiesc | .667 | 0.917 | 0.618–1.361 | ||
| 0 | 28 (26.2) | 180 (22.2) | .364 | 1.239 | 0.780–1.965 |
| 1 | 71 (66.4) | 580 (71.7) | .309 | 0.784 | 0.491–1.253 |
| ≥ 2 | 8 (7.5) | 49 (6.1) | .835 | 1.094 | 0.468–2.557 |
| Number of medical comorbiditiesc | .041∗ | 1.300 | 1.011–1.672 | ||
| 0 | 23 (21.5) | 262 (32.4) | .060 | 0.637 | 0.397–1.020 |
| 1 | 39 (36.4) | 259 (32.0) | .052 | 1.715 | 0.996–2.953 |
| ≥ 2 | 45 (42.1) | 288 (35.6) | .033∗∗ | 1.780 | 1.048–3.022 |
Comparison of aspiration and penetration between the 2 groups with and without aspiration pneumonia.
| Variables | Pneumonia group (n = 107) | Non-pneumonia group (n = 809) | OR | 95% CI | |
| 2-cc Aspiration, n (%) | |||||
| Thick-liquid | 34 (31.8) | 83 (10.3) | < .001∗ | 4.074 | 2.556–6.492 |
| Semisolid | 2 (1.9) | 32 (4.0) | .295 | 0.462 | 0.109–1.958 |
| Solid | 0 (0) | 7 (0.9) | .999 | ||
| Thin-liquid | 15 (14.0) | 66 (8.2) | .048∗ | 1.835 | 1.006–3.348 |
| 5-cc aspiration, n (%) | |||||
| Thick-liquid | 11 (10.3) | 58 (7.2) | .255 | 1.484 | 0.753–2.925 |
| Semisolid | 3 (2.8) | 14 (1.7) | .444 | 1.638 | 0.463–5.796 |
| Solid | 0 (0) | 0 (0) | |||
| Thin-liquid | 5 (4.7) | 47 (5.8) | .634 | 0.795 | 0.309–2.044 |
| 2-cc penetration, n (%) | |||||
| Thick-liquid | 4 (3.7) | 18 (2.2) | .342 | 1.707 | 0.567–5.141 |
| Semisolid | 1 (0.9) | 15 (1.9) | .503 | 0.499 | 0.065–3.819 |
| Solid | 0 (0) | 4 (0.5) | .999 | ||
| Thin-liquid | 4 (3.7) | 21 (2.6) | .498 | 1.457 | 0.491–4.329 |
| 5-cc penetration, n (%) | |||||
| Thick-liquid | 6 (5.6) | 22 (2.7) | .111 | 2.125 | 0.842–5.365 |
| Semisolid | 1 (0.9) | 7 (0.9) | .942 | 1.081 | 0.132–8.871 |
| Solid | 0 (0) | 2 (0.2) | .999 | ||
| Thin-liquid | 3 (2.8) | 13 (1.6) | .381 | 1.766 | 0.495–6.301 |
Comparison of videofluoroscopic swallowing study parameters between the 2 groups with and without aspiration pneumonia.
| Variables | Pneumonia group (n = 107) | Non-pneumonia group (n = 809) | OR | 95% CI | |
| OTTa | 10 (9.3) | 45 (5.6) | .126 | 1.750 | 0.854–3.585 |
| LEa | 15 (14.0) | 76 (9.4) | .136 | 1.573 | 0.868–2.850 |
| PDTa | 47 (43.9) | 253 (31.3) | .009∗ | 1.721 | 1.143–2.593 |
| PTTa | 38 (35.5) | 196 (24.2) | .013∗ | 1.722 | 1.123–2.641 |
| PASb | < .001∗ | 1.432 | 1.213–1.690 | ||
| 1,2,4 | 57 (53.3) | 563 (69.6) | .065 | 0.676 | 0.446–1.025 |
| 3,5,6 | 6 (0.06) | 49 (0.06) | .676 | 1.209 | 0.496–2.946 |
| 7 | 17 (15.9) | 120 (14.8) | .253 | 1.399 | 0.786–2.490 |
| 8 | 27 (25.2) | 77 (9.5) | < .001∗∗ | 3.463 | 2.067–5.803 |
Results of multivariate logistic regression model for predicting high risk of aspiration pneumonia.
| Variables | Coefficient | OR (95% CI) | |
| Sex | 0.03 | 1.027 (0.638–1.654) | .912 |
| Smoking | 0.97 | 2.632 (1.531–4.526) | < .001∗ |
| Underweight | 0.82 | 2.272 (1.312–3.935) | .003∗ |
| ≥ 2 Medical comorbidities | 0.33 | 1.389 (0.894–2.157) | .144 |
| Thick-liquid 2-cc aspiration | 1.17 | 3.231 (1.930–5.406) | < .001∗ |
| Thin-liquid 2-cc aspiration | 0.18 | 1.202 (0.617–2.342) | .589 |
| PDT | 0.47 | 1.598 (1.009–2.531) | .046∗ |
| PTT | 0.14 | 1.150 (0.700–1.889) | .581 |
| PAS level 8 | 1.32 | 3.728 (2.109–6.588) | < .001∗ |
Prediction model for the development of aspiration pneumonia.
| Variables | Definitions | Coded value | Score |
| Thick-liquid 2-cc aspiration | Aspiration during the 2-cc thick-liquid trial | Absent | 0 |
| Present | 5 | ||
| Smoking | Current or past smoker | Absent | 0 |
| Present | 4 | ||
| Underweight | Body mass index under 18.5 kg/m2 | ≥ 18.5 | 0 |
| < 18.5 | 3 | ||
| PDT[ | Duration (seconds) from when the bolus head arrives at the point where the lower edge of the mandible crosses the tongue base to when laryngeal elevation starts | ≤ 0.5 | 0 |
| > 0.5 | 2 | ||
| PAS level 8[ | Material enters the airway, passes below the vocal folds, and no effort is made to eject | Absent | 0 |
| Present | 6 | ||
| Total | 20 |
Figure 2Receiver operating characteristic curve for risk of developing aspiration pneumonia according to the development of aspiration pneumonia score. AUC = area under the curve.